Cargando…
1563MO CoVigi phase IV multicentric trial evaluating COVID-19 vaccination adverse events and immune response dynamics in cancer patients: First results on antibody and cellular immunity
| Autores principales: | , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
European Society for Medical Oncology. Published by Elsevier Ltd.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8454423/ http://dx.doi.org/10.1016/j.annonc.2021.08.1556 |
| _version_ | 1784570491710734336 |
|---|---|
| author | Obermannova, R. Demlova, R. Selingerova, I. Doubek, M. Okrouhlicova, D. Mlnarikova, M. Pilatova, K. Nevrlka, J. Lejdarova, H. Weinbergerova, B. Cermakova, Z. Valik, D. Mayer, J. Kiss, I. Zdrazilova-Dubska, L. |
| author_facet | Obermannova, R. Demlova, R. Selingerova, I. Doubek, M. Okrouhlicova, D. Mlnarikova, M. Pilatova, K. Nevrlka, J. Lejdarova, H. Weinbergerova, B. Cermakova, Z. Valik, D. Mayer, J. Kiss, I. Zdrazilova-Dubska, L. |
| author_sort | Obermannova, R. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8454423 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | European Society for Medical Oncology. Published by Elsevier Ltd. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-84544232021-09-21 1563MO CoVigi phase IV multicentric trial evaluating COVID-19 vaccination adverse events and immune response dynamics in cancer patients: First results on antibody and cellular immunity Obermannova, R. Demlova, R. Selingerova, I. Doubek, M. Okrouhlicova, D. Mlnarikova, M. Pilatova, K. Nevrlka, J. Lejdarova, H. Weinbergerova, B. Cermakova, Z. Valik, D. Mayer, J. Kiss, I. Zdrazilova-Dubska, L. Ann Oncol Article European Society for Medical Oncology. Published by Elsevier Ltd. 2021-09 2021-09-21 /pmc/articles/PMC8454423/ http://dx.doi.org/10.1016/j.annonc.2021.08.1556 Text en Copyright © 2021 European Society for Medical Oncology. Published by Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Article Obermannova, R. Demlova, R. Selingerova, I. Doubek, M. Okrouhlicova, D. Mlnarikova, M. Pilatova, K. Nevrlka, J. Lejdarova, H. Weinbergerova, B. Cermakova, Z. Valik, D. Mayer, J. Kiss, I. Zdrazilova-Dubska, L. 1563MO CoVigi phase IV multicentric trial evaluating COVID-19 vaccination adverse events and immune response dynamics in cancer patients: First results on antibody and cellular immunity |
| title | 1563MO CoVigi phase IV multicentric trial evaluating COVID-19 vaccination adverse events and immune response dynamics in cancer patients: First results on antibody and cellular immunity |
| title_full | 1563MO CoVigi phase IV multicentric trial evaluating COVID-19 vaccination adverse events and immune response dynamics in cancer patients: First results on antibody and cellular immunity |
| title_fullStr | 1563MO CoVigi phase IV multicentric trial evaluating COVID-19 vaccination adverse events and immune response dynamics in cancer patients: First results on antibody and cellular immunity |
| title_full_unstemmed | 1563MO CoVigi phase IV multicentric trial evaluating COVID-19 vaccination adverse events and immune response dynamics in cancer patients: First results on antibody and cellular immunity |
| title_short | 1563MO CoVigi phase IV multicentric trial evaluating COVID-19 vaccination adverse events and immune response dynamics in cancer patients: First results on antibody and cellular immunity |
| title_sort | 1563mo covigi phase iv multicentric trial evaluating covid-19 vaccination adverse events and immune response dynamics in cancer patients: first results on antibody and cellular immunity |
| topic | Article |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8454423/ http://dx.doi.org/10.1016/j.annonc.2021.08.1556 |
| work_keys_str_mv | AT obermannovar 1563mocovigiphaseivmulticentrictrialevaluatingcovid19vaccinationadverseeventsandimmuneresponsedynamicsincancerpatientsfirstresultsonantibodyandcellularimmunity AT demlovar 1563mocovigiphaseivmulticentrictrialevaluatingcovid19vaccinationadverseeventsandimmuneresponsedynamicsincancerpatientsfirstresultsonantibodyandcellularimmunity AT selingerovai 1563mocovigiphaseivmulticentrictrialevaluatingcovid19vaccinationadverseeventsandimmuneresponsedynamicsincancerpatientsfirstresultsonantibodyandcellularimmunity AT doubekm 1563mocovigiphaseivmulticentrictrialevaluatingcovid19vaccinationadverseeventsandimmuneresponsedynamicsincancerpatientsfirstresultsonantibodyandcellularimmunity AT okrouhlicovad 1563mocovigiphaseivmulticentrictrialevaluatingcovid19vaccinationadverseeventsandimmuneresponsedynamicsincancerpatientsfirstresultsonantibodyandcellularimmunity AT mlnarikovam 1563mocovigiphaseivmulticentrictrialevaluatingcovid19vaccinationadverseeventsandimmuneresponsedynamicsincancerpatientsfirstresultsonantibodyandcellularimmunity AT pilatovak 1563mocovigiphaseivmulticentrictrialevaluatingcovid19vaccinationadverseeventsandimmuneresponsedynamicsincancerpatientsfirstresultsonantibodyandcellularimmunity AT nevrlkaj 1563mocovigiphaseivmulticentrictrialevaluatingcovid19vaccinationadverseeventsandimmuneresponsedynamicsincancerpatientsfirstresultsonantibodyandcellularimmunity AT lejdarovah 1563mocovigiphaseivmulticentrictrialevaluatingcovid19vaccinationadverseeventsandimmuneresponsedynamicsincancerpatientsfirstresultsonantibodyandcellularimmunity AT weinbergerovab 1563mocovigiphaseivmulticentrictrialevaluatingcovid19vaccinationadverseeventsandimmuneresponsedynamicsincancerpatientsfirstresultsonantibodyandcellularimmunity AT cermakovaz 1563mocovigiphaseivmulticentrictrialevaluatingcovid19vaccinationadverseeventsandimmuneresponsedynamicsincancerpatientsfirstresultsonantibodyandcellularimmunity AT valikd 1563mocovigiphaseivmulticentrictrialevaluatingcovid19vaccinationadverseeventsandimmuneresponsedynamicsincancerpatientsfirstresultsonantibodyandcellularimmunity AT mayerj 1563mocovigiphaseivmulticentrictrialevaluatingcovid19vaccinationadverseeventsandimmuneresponsedynamicsincancerpatientsfirstresultsonantibodyandcellularimmunity AT kissi 1563mocovigiphaseivmulticentrictrialevaluatingcovid19vaccinationadverseeventsandimmuneresponsedynamicsincancerpatientsfirstresultsonantibodyandcellularimmunity AT zdrazilovadubskal 1563mocovigiphaseivmulticentrictrialevaluatingcovid19vaccinationadverseeventsandimmuneresponsedynamicsincancerpatientsfirstresultsonantibodyandcellularimmunity |